BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37222345)

  • 1. Fecal microbiota transplantation and its repercussions in patients with melanoma refractory to anti-PD-1 therapy: scope review.
    Barbosa EC; Bucar EEC; Jubé GR; Silveira LB; Silva NCD; Faria PCC; Ramos PLC; Moraes VRY; Barros JOB
    Rev Col Bras Cir; 2023; 50():e20233490. PubMed ID: 37222345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
    Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
    BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Routy B; Lenehan JG; Miller WH; Jamal R; Messaoudene M; Daisley BA; Hes C; Al KF; Martinez-Gili L; Punčochář M; Ernst S; Logan D; Belanger K; Esfahani K; Richard C; Ninkov M; Piccinno G; Armanini F; Pinto F; Krishnamoorthy M; Figueredo R; Thebault P; Takis P; Magrill J; Ramsay L; Derosa L; Marchesi JR; Parvathy SN; Elkrief A; Watson IR; Lapointe R; Segata N; Haeryfar SMM; Mullish BH; Silverman MS; Burton JP; Maleki Vareki S
    Nat Med; 2023 Aug; 29(8):2121-2132. PubMed ID: 37414899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.
    Davar D; Dzutsev AK; McCulloch JA; Rodrigues RR; Chauvin JM; Morrison RM; Deblasio RN; Menna C; Ding Q; Pagliano O; Zidi B; Zhang S; Badger JH; Vetizou M; Cole AM; Fernandes MR; Prescott S; Costa RGF; Balaji AK; Morgun A; Vujkovic-Cvijin I; Wang H; Borhani AA; Schwartz MB; Dubner HM; Ernst SJ; Rose A; Najjar YG; Belkaid Y; Kirkwood JM; Trinchieri G; Zarour HM
    Science; 2021 Feb; 371(6529):595-602. PubMed ID: 33542131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report.
    Del Giglio A; Atui FC
    World J Clin Cases; 2023 Aug; 11(24):5830-5834. PubMed ID: 37727718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal transplantation for treatment of inflammatory bowel disease.
    Imdad A; Nicholson MR; Tanner-Smith EE; Zackular JP; Gomez-Duarte OG; Beaulieu DB; Acra S
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012774. PubMed ID: 30480772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
    Baruch EN; Youngster I; Ben-Betzalel G; Ortenberg R; Lahat A; Katz L; Adler K; Dick-Necula D; Raskin S; Bloch N; Rotin D; Anafi L; Avivi C; Melnichenko J; Steinberg-Silman Y; Mamtani R; Harati H; Asher N; Shapira-Frommer R; Brosh-Nissimov T; Eshet Y; Ben-Simon S; Ziv O; Khan MAW; Amit M; Ajami NJ; Barshack I; Schachter J; Wargo JA; Koren O; Markel G; Boursi B
    Science; 2021 Feb; 371(6529):602-609. PubMed ID: 33303685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients.
    Fortman D; Avellan MGP; Hurd D; Schwartz M; Dubner H; Hewitt C; Berton S; Ernst S; Rose A; Zarour HWH; Davar D
    Melanoma Res; 2023 Apr; 33(2):136-148. PubMed ID: 36806616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incongruence between dominant commensal donor microbes in recipient feces post fecal transplant and response to anti-PD-1 immunotherapy.
    Koo H; Morrow CD
    BMC Microbiol; 2021 Sep; 21(1):251. PubMed ID: 34544375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal microbiota transplantation - new possibility to influence the results of therapy of cancer patients.
    Křížová L; Benešová I; Špaček J; Petruželka L; Vočka M
    Klin Onkol; 2022; 35(6):436-440. PubMed ID: 36513509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal Microbiota Transplant in Immunotherapy-Resistant Melanoma: What Can We Expect in the Near Future?
    Ferreira A; Neves MT; Baleiras A; Malheiro M; Martins A
    Cureus; 2022 Dec; 14(12):e32586. PubMed ID: 36654598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
    Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis.
    Hui W; Li T; Liu W; Zhou C; Gao F
    PLoS One; 2019; 14(1):e0210016. PubMed ID: 30673716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of intestinal graft-versus-host disease with unrelated donor fecal microbiota transplantation capsules: A case report.
    Mao D; Jiang Q; Sun Y; Mao Y; Guo L; Zhang Y; Man M; Ouyang G; Sheng L
    Medicine (Baltimore); 2020 Sep; 99(38):e22129. PubMed ID: 32957333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy analysis of fecal microbiota transplantation in the treatment of 2010 patients with intestinal disorders].
    Li N; Tian HL; Chen QY; Yang B; Ma CL; Lin ZL; Zhang XY; Zhao D; Huang ZX; Jiang J; Qin HL
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):861-868. PubMed ID: 31550826
    [No Abstract]   [Full Text] [Related]  

  • 17. Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment.
    Xu H; Cao C; Ren Y; Weng S; Liu L; Guo C; Wang L; Han X; Ren J; Liu Z
    Front Immunol; 2022; 13():949490. PubMed ID: 36177041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology.
    Jamal R; Messaoudene M; de Figuieredo M; Routy B
    Semin Immunol; 2023 May; 67():101754. PubMed ID: 37003055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation].
    Zheng YY; Yang XT; Lin GQ; Bian MR; Si YJ; Zhang XX; Zhang YM; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):401-407. PubMed ID: 37550190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.